Media stories about GlaxoSmithKline (NYSE:GSK) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news impact score of 0.16 on Accern’s scale. Accern also gave media headlines about the pharmaceutical company an impact score of 46.4397444786142 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Glaxo CEO Walmsley’s Shakeup Continues With Job Cuts in Africa – Bloomberg (bloomberg.com)
- Hot Stock in Focus – GlaxoSmithKline plc (NYSE: GSK) – Alpha Beta Stock (alphabetastock.com)
- Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb (finance.yahoo.com)
- GlaxoSmithKline plc to Post FY2022 Earnings of $3.75 Per Share, Jefferies Group Forecasts (GSK) (americanbankingnews.com)
- J&J (JNJ) Hits New 52-Week High: What's Driving the Stock? (finance.yahoo.com)
GSK has been the subject of a number of research analyst reports. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and increased their price target for the stock from $35.04 to $35.85 in a report on Monday, November 27th. ValuEngine cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Cowen set a $38.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Monday, December 11th. Finally, Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and an average target price of $38.57.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. research analysts anticipate that GlaxoSmithKline will post 2.92 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Investors of record on Friday, November 10th were paid a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.27%. GlaxoSmithKline’s dividend payout ratio is presently 154.55%.
In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3146508/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-glaxosmithkline-gsk-share-price.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.